Key Takeaways

• Sonrai helped IVBH unlock meaningful insights from legacy RNA-Seq and PCR data - enabling biomarker validation that would not have been feasible without dedicated data science support
• By integrating public validation datasets alongside proprietary data, Sonrai strengthened the external evidence base for IVBH's liquid biopsy technology across breast cancer, lung cancer, and NAFLD
• The engagement helped IVBH build a credible investment case and accelerate discussions around commercialisation - directly addressing the reproducibility and validation challenges that commonly stall diagnostic development programmes

Jump to section

Case Study Highlights

In this diagnostic case study we demonstrate how Sonrai helped IVBH unlock new insights from existing data to discover biomarkers and accelerate the development of a new diagnostic product. Sonrai collaborated with the client throughout, providing data science support and expert guidance to get a deeper understanding of the underlying data. This is one example of the broader diagnostic development support Sonrai offers to companies building precision diagnostic products.

"The Sonrai relationship has truly been the biggest win for IVBH of 2022."

Marty Keiser

Founder CEO, IV Bioholdings

IV Bioholdings - The Client

Founded in 2018, IVBH is dedicated to revolutionising the way diseases are detected and diagnosed. An emerging leader in liquid biopsy technology, IVBH specialises in early detection precision diagnostics - with the goal of creating highly accurate, affordable, and accessible diagnostic solutions that can detect disease in its earliest stages (stage 0-II) and eliminate unnecessary invasive procedures.

IVBH's flagship liquid biopsy programmes are focused on three specific diseases: breast cancer, lung cancer, and non-alcoholic fatty liver disease (NAFLD). By detecting these conditions at an early stage when treatment is most effective, IVBH's non-invasive technology aims to provide highly accurate results with minimal discomfort for the patient - contributing to the broader movement in precision medicine.

The Challenge

Like any company at the cutting edge of precision medicine, IVBH faced a number of challenges they needed to overcome:

• Legacy data. IVBH had amassed a large volume of legacy data during the biomarker discovery phase. They needed access to powerful, secure analysis tools and expert data science support to fully exploit their datasets and create visualisations that would help present findings to prospective partners.
• Identification of independent validation datasets. IVBH needed expert support to source and integrate relevant new datasets to further support the effectiveness of their liquid biopsy technology through external validation studies.
• Reproducibility. This is a common challenge in biomarker development. Proving the validity of a new biomarker or molecular signature without robust data science support is one of the most persistent causes of diagnostic programme failure. The scientific reproducibility challenge is well documented across the biomarker discovery field.
• Lack of in-house data science expertise. To further develop and optimise their technology, IVBH required a team of experts who could help analyse the data and select and apply the best methodologies to refine their signatures.
• Investment readiness. To build the business case for further investment, IVBH needed to add robustness to their workflows and demonstrate that their technology is viable - producing visualisations that efficiently communicated the power and potential of their technology to both specialist and non-specialist audiences.

The Strategy

The Sonrai team worked directly with IVBH to address each of these challenges:

• Unlock the full potential of their data. Sonrai's AI data analytics platform flagged the important features of their dataset and allowed IVBH to focus on the most relevant information - making it much easier to extract meaningful insights and make data-driven decisions. This approach mirrors the end-to-end AI biomarker discovery workflow Sonrai applies across a range of client programmes.
• Vital data science support. Sonrai provided IVBH with dedicated data science support, helping them analyse, interpret, and share discoveries from their data. With the help of Sonrai's team of experts, IVBH was able to get a deeper understanding of their data and make sense of the complex information they had collected.
• AI and ML. Sonrai incorporated AI and ML applications to refine gene signatures - crucial for detecting diseases at an early stage. This helped IVBH improve the accuracy of their diagnostic tests and make them more effective in detecting diseases. The RNA-Seq data processing and biomarker validation followed established analytical frameworks underpinned by reproducible, version-controlled workflows.
• Multidisciplinary collaboration. Sonrai collaborated directly with IVBH's lab partner, P4 Diagnostix, enabling more effective processing and interrogation of new data and sharing of resources and expertise - creating a highly efficient bridge between research and development and clinical workflows.
• Clinical assay development experience. Sonrai biomarker experts helped IVBH create robust study designs for the validation of their biomarkers, creating greater confidence in the resultant data.
• Dedicated project management. Sonrai assigned an experienced project manager to the programme, helping IVBH to stay on track and overcome challenges during their research and development.

"You are truly a spectacular partner!"

Marty Keiser

Founder CEO, IV Bioholdings

Results

No cost. No risk.

Want to unlock insights from your diagnostic data?

Challenge Sonrai to find what others haven't. We'll apply our AI biomarker discovery approach to your dataset - at no cost.

Explore the free showcase

Case Study

GenoMe Diagnostics - Biomarker Discovery

Use Case

AI Biomarker Discovery Workflow

Article

A Guide to Biomarker Validation

Talk to our team

Sonrai acts as an extension of your team, combining scientific expertise, transparent and reproducible analysis, and a governed research environment to generate decision-ready evidence that can be revisited, reproduced, and built upon throughout the life of a programme.

Book a demo